Human antibodies and hybridomas最新文献_第4页

Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-tau. 接种分泌融合蛋白RM4/IFN-tau的骨髓瘤细胞的抗肿瘤免疫特性

Human antibodies and hybridomas Pub Date : 1996-01-01 DOI: 10.3233/HAB-1996-7103

Y. Qi, T. Moyana, Y. Chen, J. Xiang

{"title":"Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-tau.","authors":"Y. Qi, T. Moyana, Y. Chen, J. Xiang","doi":"10.3233/HAB-1996-7103","DOIUrl":"https://doi.org/10.3233/HAB-1996-7103","url":null,"abstract":"Our previous study showed that the injection of mouse myeloma VKCK/RM4-IFN-tau cells secreting the fusion protein RM4/IFN-tau to syngeneic BALB/c mice resulted in tumor regression in 70% of mice after tumor inoculation. In this study, the VKCK/RM4-IFN-tau cell line was used to characterize the protective immunity subsequent to tumor inoculation. Our histologic findings demonstrated that, in the primary response to VKCK/RM4-IFN-tau inoculation, tumor regression is associated with macrophage infiltration. This macrophage-dominated regression further leads to a protective immunity against the 2nd challenge of parental VKCK tumor cells. FACS analysis and chromium release assays showed that the majority of T lymphocytes that mediated this anti-tumor immunity were CD8+ cytotoxic T lymphocytes (CTLs). Our animal studies further showed that the VKCK/RM4-IFN-tau cells were able to grow as aggressively as the parental VKCK cells in T lymphocyte deficient nude mice. The protective immunity started 7 days, became complete 10 days following and lasted up to at least 12 months subsequent to the tumor inoculation. The adoptive transfer of T lymphocyte-enriched spleen cells or CTLs also conferred significant protection against tumor growth of parental VKCK cells (p < 0.01). These data thus support the notion that genetically engineered tumor cells secreting IFN-tau may have potential use as tumor vaccines in preventing the development of tumor recurrence and/or metastases following the surgical removal of the primary tumors.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"7 1 1","pages":"21-6"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-1996-7103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69906061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Evidence for restricted diversity of antigen-specific human antibodies in immunized hu-PBL-SCID mice. 免疫hu-PBL-SCID小鼠中抗原特异性人抗体有限多样性的证据。

Human antibodies and hybridomas Pub Date : 1996-01-01 DOI: 10.3233/HAB-1996-7306

R. Bazin, M. Chevrier, R. Delage, R. Lemieux

{"title":"Evidence for restricted diversity of antigen-specific human antibodies in immunized hu-PBL-SCID mice.","authors":"R. Bazin, M. Chevrier, R. Delage, R. Lemieux","doi":"10.3233/HAB-1996-7306","DOIUrl":"https://doi.org/10.3233/HAB-1996-7306","url":null,"abstract":"Previous studies have revealed that specific human humoral immune responses could be produced in immunized SCID mice after engraftment of human lymphocytes (hu-PBL-SCID). On the other hand, the engrafted repertoire of B cell clones is known to be skewed in hu-PBL-SCID with the corresponding production of only a limited set of major human antibodies. In this work, we have analyzed the diversity of tetanus toxoid-specific human antibodies produced in immunized hu-PBL-SCID mice in comparison with the total serum antibody population using zone electrophoresis followed by blotting. The results showed that the diversity of tetanus toxoid-specific antibody population was more restricted than that of the total human antibody population, with some animal sera containing a single band of tetanus toxoid-specific antibody molecule, in clear contrast to the polyclonal response of the PBL donor. Absorption experiments showed tetanus toxoid-specific antibodies could account for a significant proportion (up to 10%) of the total human antibodies present in hu-PBL-SCID mouse sera. The inability to expand a high number of different antigen-specific B cell clones in immunized hu-PBL-SCID mice represents an important intrinsic limitation of this animal model which may be caused by defects in T cell help.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"7 3 1","pages":"129-34"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-1996-7306","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69906743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Comparative study of the role of serum levels of p53 antigen and its tumor cell concentration in colon cancer detection. 血清p53抗原水平及其肿瘤细胞浓度在结肠癌检测中的比较研究。

Human antibodies and hybridomas Pub Date : 1996-01-01 DOI: 10.3233/HAB-1996-7305

I. Zusman, B. Sandler, P. Gurevich, R. Zusman, P. Smirnoff, Y. Tendler, D. Bass, A. Shani, E. Idelevich, R. Pfefferman, B. Davidovich, M. Huszar, J. Glick

{"title":"Comparative study of the role of serum levels of p53 antigen and its tumor cell concentration in colon cancer detection.","authors":"I. Zusman, B. Sandler, P. Gurevich, R. Zusman, P. Smirnoff, Y. Tendler, D. Bass, A. Shani, E. Idelevich, R. Pfefferman, B. Davidovich, M. Huszar, J. Glick","doi":"10.3233/HAB-1996-7305","DOIUrl":"https://doi.org/10.3233/HAB-1996-7305","url":null,"abstract":"The role of serum levels of p53 antigen in detection of colon cancer was studied in different groups of cancer and noncancer patients and was compared with the results of immunohistochemical analyses. The p53 antigen was isolated from the human serum as a cytoplasmic fraction using the recently described new type of columns for affinity chromatography, gel fiberglass columns (Zusman and Zusman, 1995). Its concentration was detected by high performance liquid chromatography. The serum level of the p53 antigen significantly increased in cancer patients (3.6 mg ml(-1)) as compared to its concentration in patients with benign tumors (1.7 mg ml(-1)) or in patients with noncancer disorders (0.49 mg ml(-1)), and this was found to be a result of higher concentration of p53 protein in tumor cells. Coefficient of correlation between cellular concentration of p53 protein and its serum level was 0.44 in noncancer lesions and 0.48 in cancer patients. Serum levels of p53 antigen was shown to be highly active either in patients with noncancer lesions or in patients with cancer (r = 0.46 and 0.51 respectively), whereas the cell determination of p53 protein was effective only among noncancer patients (r = 0.61) but not in cancer patients (r = 0.22). The findings suggests that serum determination of p53 antigen can perhaps reveal this oncoprotein already in the early stages of cancer or even predict the putative development of cancer. The possibility to use the serum-levels of p53 antigen in the follow up patients with chronic diseases and to detect transformation of these diseases into cancer, or monitoring former cancer patients in order to detect as early as possible the incidence of recurrent cancer is discussed.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"7 3 1","pages":"123-8"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-1996-7305","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69906733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. 临床证据表明，人单克隆抗独特型抗体105AD7通过刺激抗肿瘤t细胞反应来延缓肿瘤生长。

Human antibodies and hybridomas Pub Date : 1995-01-01 DOI: 10.3233/HAB-1995-6205

Buckley Dt, Robins Ar, L. Durrant

{"title":"Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.","authors":"Buckley Dt, Robins Ar, L. Durrant","doi":"10.3233/HAB-1995-6205","DOIUrl":"https://doi.org/10.3233/HAB-1995-6205","url":null,"abstract":"A human monoclonal anti-idiotypic antibody, 105AD7, which mimics a colorectal tumor associated antigen, 791Tgp72, has been developed. A Phase I trial in advanced colorectal cancer patients showed that 105AD7 therapy was nontoxic and that immunised patients had prolonged survival when compared to a contemporary group of patients treated in the same center. There is accumulating clinical evidence that 105AD7 delays tumor growth by stimulating anti-tumor T-cell responses. Stimulation of helper T-cells was exemplified in the phase I study as 105AD7 immunized patients showed antigen specific T-cell blastogenesis responses and enhanced IL-2 production. Further evidence was obtained from a new clinical study in which colorectal cancer patients were immunized prior to tumor resection. Immune infiltrating cells were analysed by immunohistochemistry and effector cell function was studied in immune cells from peripheral blood and tumor draining lymph nodes. Both activated CD4 and natural killer (NK) cells were observed at the tumor site, which is of interest as NK cells are rarely found in colorectal tumors. Effector studies confirmed that NK activity was enhanced in 3/6 patients. Increased autologous tumor killing was also found in 3/4 patients and accumulation of CD8RO cells following 105AD7 immunization also suggested that CD8 T cells were being stimulated.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"6 2 1","pages":"68-72"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-1995-6205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69906114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Comparison of three human-murine heteromyeloma cell lines for formation of human hybridomas after electrofusion with human peripheral blood lymphocytes from meningococcal cases and carriers. 三种人鼠异骨髓瘤细胞系与脑膜炎球菌病例和携带者外周血淋巴细胞电融合后形成人杂交瘤的比较。

Human antibodies and hybridomas Pub Date : 1995-01-01

A A Delvig, B Koumaré, R W Glaser, J F Wang, S Jahn, M Achtman

引用次数: 0

The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. 经-半乳糖苷酶处理后，人单克隆IgG抗d的生物活性降低。

Human antibodies and hybridomas Pub Date : 1995-01-01

B M Kumpel, Y Wang, H L Griffiths, A G Hadley, G A Rook

{"title":"The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment.","authors":"B M Kumpel, Y Wang, H L Griffiths, A G Hadley, G A Rook","doi":"","DOIUrl":"","url":null,"abstract":"The contribution to IgG effector function of exposed galactose residues on the oligosaccharide chains in IgG has been tested experimentally. We studied a human monoclonal antibody (BRAD-5) to the Rh D blood group antigen. The preparation used contained a very low percentage of agalactosyl IgG (3.6%). After digestion with beta-galactosidase there was an increase in terminal GlcNAc indicating an increase in % agalactosyl IgG to approximately 30%. Comparison was made of the Fc receptor-(Fc gamma R)-mediated functional interactions of the two glycoforms of BRAD-5 in assays which measured the recognition and destruction of sensitised erythrocytes by various effector cells. After beta-galactosidase treatment, there was a slight reduction in Fc gamma RI-mediated adherence of erythrocytes to U937 cells and phagocytosis of erythrocytes by monocytes. Fc gamma RII-mediated binding of erythrocytes to K562 cells was also reduced. However there was little difference in adherence of erythrocytes to either Daudi cells (via Fc gamma RII) or NK cells (via Fc gamma RIII). There was a consistent reduction in lysis of erythrocytes mediated through Fc gamma RIII on K cells with the beta-galactosidase treated anti-D. Overall the results showed that reduced levels of galactose on IgG anti-D were associated with reduced biological activity in these assays, but the experiments failed to cast light on the physiological role of the agalactosyl glycoform of IgG.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"6 3","pages":"82-8"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19577155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. 临床证据表明，人单克隆抗独特型抗体105AD7通过刺激抗肿瘤t细胞反应来延缓肿瘤生长。

Human antibodies and hybridomas Pub Date : 1995-01-01

D T Buckley, A R Robins, L G Durrant

{"title":"Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.","authors":"D T Buckley, A R Robins, L G Durrant","doi":"","DOIUrl":"","url":null,"abstract":"A human monoclonal anti-idiotypic antibody, 105AD7, which mimics a colorectal tumor associated antigen, 791Tgp72, has been developed. A Phase I trial in advanced colorectal cancer patients showed that 105AD7 therapy was nontoxic and that immunised patients had prolonged survival when compared to a contemporary group of patients treated in the same center. There is accumulating clinical evidence that 105AD7 delays tumor growth by stimulating anti-tumor T-cell responses. Stimulation of helper T-cells was exemplified in the phase I study as 105AD7 immunized patients showed antigen specific T-cell blastogenesis responses and enhanced IL-2 production. Further evidence was obtained from a new clinical study in which colorectal cancer patients were immunized prior to tumor resection. Immune infiltrating cells were analysed by immunohistochemistry and effector cell function was studied in immune cells from peripheral blood and tumor draining lymph nodes. Both activated CD4 and natural killer (NK) cells were observed at the tumor site, which is of interest as NK cells are rarely found in colorectal tumors. Effector studies confirmed that NK activity was enhanced in 3/6 patients. Increased autologous tumor killing was also found in 3/4 patients and accumulation of CD8RO cells following 105AD7 immunization also suggested that CD8 T cells were being stimulated.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"6 2","pages":"68-72"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18500913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A human monoclonal antibody to carbohydrate moiety of carcinoembryonic antigen. 人抗癌胚抗原碳水化合物部分的单克隆抗体。

Human antibodies and hybridomas Pub Date : 1995-01-01

K Tsukazaki, K Kuroda, K Mochizuki, K Kubushiro, T Fukuchi, M Kato, S Hashizume, S Nozawa

{"title":"A human monoclonal antibody to carbohydrate moiety of carcinoembryonic antigen.","authors":"K Tsukazaki, K Kuroda, K Mochizuki, K Kubushiro, T Fukuchi, M Kato, S Hashizume, S Nozawa","doi":"","DOIUrl":"","url":null,"abstract":"Hybridoma BSRF-S-97, secreting a human monoclonal antibody of IgG1 subclass reactive to the carcinoembryonic antigen, was generated by fusing the regional lymph node lymphocytes from a cervical cancer patient with RF-S1 human-mouse heteromyeloma fusion line. This monoclonal antibody was found specifically reactive to carinoembryonic antigen-producing cell lines, including those of cervical cancer (SKG-II), mucinous type ovarian cancer (RMUG-L), stomach cancer (MKN-45), and lung cancer (PC-10). The monoclonal antibody reactivity with pepsin- and periodate-treated carcinoembryonic antigen demonstrated that this monoclonal antibody recognizes the carbohydrate moiety of carcinoembryonic antigen specifically. Possibilities of the monoclonal antibody reaction with mucin and blood-group antigens were excluded by the comparative studies with a placental mucin-containing protein which reacted with carcinoembryonic antigen-specific rabbit polyclonal antibody. The monoclonal antibody conjugated with Pseudomonas exotoxin showed potent regression effects on the growth of the MKN-45 cell line in both the dish culture and xenografted nude mice, indicating potential usefulness of this human monoclonal antibody as a promising tumor targeting vehicle.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"6 4","pages":"145-52"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19663090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Macrophage subpopulations in the thymic hyperplasia of patients with myasthenia gravis. 巨噬细胞亚群在重症肌无力患者胸腺增生中的作用。

Human antibodies and hybridomas Pub Date : 1995-01-01

J Zhang, S Cohen-Kaminsky, S Berrih-Aknin

{"title":"Macrophage subpopulations in the thymic hyperplasia of patients with myasthenia gravis.","authors":"J Zhang, S Cohen-Kaminsky, S Berrih-Aknin","doi":"","DOIUrl":"","url":null,"abstract":"Macrophages were studied in sections of the thymus from patients with Myasthenia Gravis, using a panel of monoclonal antibodies against the monocyte/macrophage lineage. In normal areas, CD14 and CD35 were preferentially expressed in the medulla while RM3/1 and 25F9 markers stained essentially cortical macrophages. CD11c-labelled cells were densely located throughout the thymus. The antibody 27E10 recognized clusters of cells located around or in the perivascular areas, that could be migrating monocytes. In the germinal centers, cells were stained with CD14, CD35, CD11c and 25F9 but not with RM3/1 and 27E10 markers. The numbers of CD14- and CD35-positive cells were significantly increased in Myasthenia Gravis thymic hyperplasia compared to control thymus (p < 0.025 and p < 0.01, respectively). This increase was clearly due to the higher number of positive cells in the germinal centers and in the areas surrounding the lymphoid follicles. The potential role of these cells in accessory cell function and antigen presentation could be relevant in terms of intrathymic sensitization and autoantibody production that have been demonstrated in thymic hyperplasia from Myasthenia Gravis patients.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"6 4","pages":"153-60"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19663091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immortalization of plasma cells by plasmid DNA and its hybridoma. 质粒DNA对浆细胞的永生化及其杂交瘤。

Human antibodies and hybridomas Pub Date : 1995-01-01

T Kanki, S Takeuchi

引用次数: 0